본 바이올로직스(BBLG)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.66 (-2.86%), 시가총액 $0.00B, 52주 범위 $0.75 ~ $6.20.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL
본 바이올로직스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
본 바이올로직스의 현재 주가는 $0.66 (-2.86%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
본 바이올로직스의 시가총액은 약 $0.00B입니다.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical dev